Lacroix, A. Et Al. 2020. Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION , vol.43, no.11 , 1613-1622.

Lacroix, A., Bronstein, M. D., Schopohl, J., Delibasi, T., Salvatori, R., Li, Y., ... Barkan, A.(2020). Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION , vol.43, no.11, 1613-1622.

Lacroix, A. Et Al. "Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study," JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION , vol.43, no.11, 1613-1622, 2020

Lacroix, A. Et Al. "Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study." JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION , vol.43, no.11, pp.1613-1622, 2020

Lacroix, A. Et Al. (2020) . "Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study." JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION , vol.43, no.11, pp.1613-1622.

@article{article, author={A. Lacroix Et Al. }, title={Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study}, journal={JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION}, year=2020, pages={1613-1622} }